Breaking Down SG&A Expenses: GSK plc vs Sarepta Therapeutics, Inc.

A Comparative Analysis of SG&A Expenses: GSK plc vs. Sarepta Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of GSK plc and Sarepta Therapeutics, Inc. from 2014 to 2023. GSK, a global healthcare giant, consistently reported SG&A expenses averaging around $9.8 billion annually, peaking in 2020. In contrast, Sarepta, a leader in genetic medicine, showed a significant upward trend, with expenses growing nearly tenfold from 2014 to 2023. This stark contrast highlights GSK's established market presence and Sarepta's rapid expansion. The data underscores the strategic investments both companies are making in their operations, with GSK focusing on maintaining its market position and Sarepta on scaling its innovative therapies. As the industry continues to grow, these financial insights provide a window into the strategic priorities of these pharmaceutical leaders.